United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by TFB Advisors LLC

TFB Advisors LLC lessened its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 2,262 shares of the biotechnology company’s stock after selling 29 shares during the period. TFB Advisors LLC’s holdings in United Therapeutics were worth $798,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in UTHR. World Investment Advisors LLC bought a new stake in United Therapeutics in the third quarter worth about $139,206,000. FMR LLC raised its holdings in shares of United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. Assetmark Inc. lifted its stake in United Therapeutics by 56.9% during the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after purchasing an additional 152,249 shares during the last quarter. Franklin Resources Inc. boosted its holdings in United Therapeutics by 97.7% during the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in United Therapeutics by 32.5% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 343,744 shares of the biotechnology company’s stock worth $123,181,000 after buying an additional 84,369 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 255 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 121,864 shares of company stock valued at $44,516,965 over the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Stock Up 2.2 %

Shares of UTHR stock opened at $353.31 on Wednesday. United Therapeutics Co. has a 12-month low of $210.64 and a 12-month high of $417.82. The firm has a fifty day moving average of $362.06 and a 200-day moving average of $358.24. The firm has a market capitalization of $15.78 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on UTHR. LADENBURG THALM/SH SH increased their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. HC Wainwright upped their target price on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.